Emergency Use Authorization requested for REGN-COV2 by Regeneron

8 October 2020

Subsequent to discussions with regulatory authorities, Regeneron Pharmaceuticals (Nasdaq: REGN) says it has submitted a request to the US Food and Drug Administration for an Emergency Use Authorization (EUA) for its REGN-COV2 investigational antibody combination for the treatment of COVID-19.

News of Regeneron’s decision saw the firm’s shares gain more than 4% to $616.03 in pre-market trading today.

Under Regeneron’s agreement with the US government for the initial doses of REGN-COV2, if an EUA is granted, the government has committed to making these doses available to the American people at no cost and would be responsible for their distribution. At this time, there are doses available for around 50,000 patients, and the company expect to have doses available for 300,000 patients in total within the next few months.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK